
Organoids are in-vitro derived 3D cell aggregates derived from primary tissue or stem cells that are capable of self-renewal, self-organization and exhibit organ functionality.
The global Organoids market was valued at US$ 56 million in 2023 and is anticipated to reach US$ 185 million by 2030, witnessing a CAGR of 18.4% during the forecast period 2024-2030.
Organoids are a complex collection of cells grown in 3D culture medium that can summarize the various physiological and genomic characteristics of various tissues or organs. Organoids are micro-organs with three-dimensional structures that are cultivated in vitro using adult stem cells. They have highly similar genetic backgrounds and histological characteristics to organs in the body; they have complex structures similar to real organs and can partially simulate the physiological functions of the source tissues and organs; they simulate the endogenous environment to conduct research on tissue biology, development and regeneration, disease modeling, organ transplantation technology improvement, drug discovery/efficacy evaluation, and toxicology. Organoids refer to tissue analogs with a certain spatial structure formed by three-dimensional (3D) culture in vitro using adult stem cells or pluripotent stem cells. Although organoids are not true human organs, they can simulate real organs in structure and function, can simulate the structure and function of in vivo tissues to the greatest extent, and can be cultured stably for a long time (hence they are also called "micro-organs").
A major driver of the organoids market is the increasing demand for advanced models in drug discovery and personalized medicine. Organoids, which mimic the structure and function of real human organs, provide a more accurate representation of human biology compared to traditional cell cultures or animal models. This enables pharmaceutical companies to conduct more precise preclinical testing, reducing the time and cost of drug development. Additionally, organoids are being increasingly used in personalized medicine, where they can help tailor treatments to individual patients by predicting how they will respond to specific therapies, particularly in cancer research.
One of the main challenges in the organoids market is the complexity and high cost of organoid development and maintenance. Creating organoids that accurately replicate human organs requires sophisticated techniques and specialized equipment, making the process expensive and technically demanding. Additionally, there are still limitations in scaling up production and standardizing protocols, which hinders widespread adoption in clinical settings. Regulatory hurdles and the need for more validation studies to ensure the reliability of organoids in predicting human responses also pose barriers to market growth.
This report aims to provide a comprehensive presentation of the global market for Organoids, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Organoids.
The Organoids market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Organoids market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Organoids companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Thermo Fisher Scientific
Merck
Corning
STEMCELL Technologies
Lonza
Prellis Biologics
amsbio
Tanwang Medical
Ketu Medicine
Chuangxin International
Segment by Type
Stem Cell Source
Tumor Cell Source
Segment by Application
Precision Medicine
Pharmaceutical R&D
Academics and Research Institutes
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Organoids company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Organoids 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Stem Cell Source
1.2.3 Tumor Cell Source
1.3 麻豆原创 by Application
1.3.1 Global Organoids 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Precision Medicine
1.3.3 Pharmaceutical R&D
1.3.4 Academics and Research Institutes
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Organoids 麻豆原创 Perspective (2019-2030)
2.2 Global Organoids Growth Trends by Region
2.2.1 Global Organoids 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Organoids Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Organoids Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Organoids 麻豆原创 Dynamics
2.3.1 Organoids Industry Trends
2.3.2 Organoids 麻豆原创 Drivers
2.3.3 Organoids 麻豆原创 Challenges
2.3.4 Organoids 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Organoids Players by Revenue
3.1.1 Global Top Organoids Players by Revenue (2019-2024)
3.1.2 Global Organoids Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Organoids 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Organoids Revenue
3.4 Global Organoids 麻豆原创 Concentration Ratio
3.4.1 Global Organoids 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Organoids Revenue in 2023
3.5 Global Key Players of Organoids Head office and Area Served
3.6 Global Key Players of Organoids, Product and Application
3.7 Global Key Players of Organoids, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Organoids Breakdown Data by Type
4.1 Global Organoids Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Organoids Forecasted 麻豆原创 Size by Type (2025-2030)
5 Organoids Breakdown Data by Application
5.1 Global Organoids Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Organoids Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Organoids 麻豆原创 Size (2019-2030)
6.2 North America Organoids 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Organoids 麻豆原创 Size by Country (2019-2024)
6.4 North America Organoids 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Organoids 麻豆原创 Size (2019-2030)
7.2 Europe Organoids 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Organoids 麻豆原创 Size by Country (2019-2024)
7.4 Europe Organoids 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Organoids 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Organoids 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Organoids 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Organoids 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Organoids 麻豆原创 Size (2019-2030)
9.2 Latin America Organoids 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Organoids 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Organoids 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Organoids 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Organoids 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Organoids 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Organoids 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Thermo Fisher Scientific
11.1.1 Thermo Fisher Scientific Company Details
11.1.2 Thermo Fisher Scientific Business Overview
11.1.3 Thermo Fisher Scientific Organoids Introduction
11.1.4 Thermo Fisher Scientific Revenue in Organoids Business (2019-2024)
11.1.5 Thermo Fisher Scientific Recent Development
11.2 Merck
11.2.1 Merck Company Details
11.2.2 Merck Business Overview
11.2.3 Merck Organoids Introduction
11.2.4 Merck Revenue in Organoids Business (2019-2024)
11.2.5 Merck Recent Development
11.3 Corning
11.3.1 Corning Company Details
11.3.2 Corning Business Overview
11.3.3 Corning Organoids Introduction
11.3.4 Corning Revenue in Organoids Business (2019-2024)
11.3.5 Corning Recent Development
11.4 STEMCELL Technologies
11.4.1 STEMCELL Technologies Company Details
11.4.2 STEMCELL Technologies Business Overview
11.4.3 STEMCELL Technologies Organoids Introduction
11.4.4 STEMCELL Technologies Revenue in Organoids Business (2019-2024)
11.4.5 STEMCELL Technologies Recent Development
11.5 Lonza
11.5.1 Lonza Company Details
11.5.2 Lonza Business Overview
11.5.3 Lonza Organoids Introduction
11.5.4 Lonza Revenue in Organoids Business (2019-2024)
11.5.5 Lonza Recent Development
11.6 Prellis Biologics
11.6.1 Prellis Biologics Company Details
11.6.2 Prellis Biologics Business Overview
11.6.3 Prellis Biologics Organoids Introduction
11.6.4 Prellis Biologics Revenue in Organoids Business (2019-2024)
11.6.5 Prellis Biologics Recent Development
11.7 amsbio
11.7.1 amsbio Company Details
11.7.2 amsbio Business Overview
11.7.3 amsbio Organoids Introduction
11.7.4 amsbio Revenue in Organoids Business (2019-2024)
11.7.5 amsbio Recent Development
11.8 Tanwang Medical
11.8.1 Tanwang Medical Company Details
11.8.2 Tanwang Medical Business Overview
11.8.3 Tanwang Medical Organoids Introduction
11.8.4 Tanwang Medical Revenue in Organoids Business (2019-2024)
11.8.5 Tanwang Medical Recent Development
11.9 Ketu Medicine
11.9.1 Ketu Medicine Company Details
11.9.2 Ketu Medicine Business Overview
11.9.3 Ketu Medicine Organoids Introduction
11.9.4 Ketu Medicine Revenue in Organoids Business (2019-2024)
11.9.5 Ketu Medicine Recent Development
11.10 Chuangxin International
11.10.1 Chuangxin International Company Details
11.10.2 Chuangxin International Business Overview
11.10.3 Chuangxin International Organoids Introduction
11.10.4 Chuangxin International Revenue in Organoids Business (2019-2024)
11.10.5 Chuangxin International Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
Thermo Fisher Scientific
Merck
Corning
STEMCELL Technologies
Lonza
Prellis Biologics
amsbio
Tanwang Medical
Ketu Medicine
Chuangxin International
听
听
*If Applicable.
